FI973323A0 - Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo - Google Patents
Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivoInfo
- Publication number
- FI973323A0 FI973323A0 FI973323A FI973323A FI973323A0 FI 973323 A0 FI973323 A0 FI 973323A0 FI 973323 A FI973323 A FI 973323A FI 973323 A FI973323 A FI 973323A FI 973323 A0 FI973323 A0 FI 973323A0
- Authority
- FI
- Finland
- Prior art keywords
- exogens
- expression
- drug combination
- vivo transfection
- combination useful
- Prior art date
Links
- 238000001727 in vivo Methods 0.000 title abstract 2
- 238000001890 transfection Methods 0.000 title abstract 2
- 239000000890 drug combination Substances 0.000 title 1
- 230000003721 exogen phase Effects 0.000 title 1
- 108020004511 Recombinant DNA Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 230000002480 immunoprotective effect Effects 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9501662A FR2730411B1 (fr) | 1995-02-14 | 1995-02-14 | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
| FR9501662 | 1995-02-14 | ||
| FR9600218 | 1996-01-10 | ||
| PCT/FR1996/000218 WO1996025177A1 (fr) | 1995-02-14 | 1996-02-12 | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI973323A0 true FI973323A0 (fi) | 1997-08-13 |
| FI973323A FI973323A (fi) | 1997-08-13 |
| FI119176B FI119176B (fi) | 2008-08-29 |
Family
ID=9476106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI973323A FI119176B (fi) | 1995-02-14 | 1997-08-13 | Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20030004091A1 (fi) |
| EP (1) | EP0809516B1 (fi) |
| JP (1) | JPH11500430A (fi) |
| KR (1) | KR100402540B1 (fi) |
| AT (1) | ATE204481T1 (fi) |
| AU (1) | AU717218B2 (fi) |
| BR (1) | BR9607310A (fi) |
| CA (1) | CA2211039C (fi) |
| CZ (1) | CZ258197A3 (fi) |
| DE (1) | DE69614668T2 (fi) |
| DK (1) | DK0809516T3 (fi) |
| ES (1) | ES2163612T3 (fi) |
| FI (1) | FI119176B (fi) |
| FR (1) | FR2730411B1 (fi) |
| GR (1) | GR3036438T3 (fi) |
| HU (1) | HU222991B1 (fi) |
| IL (1) | IL117116A0 (fi) |
| MX (1) | MX9706017A (fi) |
| NO (1) | NO320072B1 (fi) |
| PT (1) | PT809516E (fi) |
| SK (1) | SK282235B6 (fi) |
| WO (1) | WO1996025177A1 (fi) |
| ZA (1) | ZA961161B (fi) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451571B1 (en) | 1994-05-02 | 2002-09-17 | University Of Washington | Thymidine kinase mutants |
| WO1998008539A1 (en) * | 1996-08-26 | 1998-03-05 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| CA2308017A1 (en) | 1997-10-30 | 1999-05-14 | Erik S. Falck-Pedersen | A method of inhibiting an immune response to a recombinant vector |
| JP2003523721A (ja) | 1998-12-31 | 2003-08-12 | カイロン コーポレイション | 抗原性ｈｉｖｃ型ポリペプチドをコードするポリヌクレオチド、ポリペプチド、およびそれらの使用 |
| WO2000074688A1 (en) * | 1999-06-08 | 2000-12-14 | The Children's Hospital Of Philadelphia | Methods for preventing formation of inhibitory antibodies in the setting of gene therapy |
| FR2799472B1 (fr) * | 1999-10-07 | 2004-07-16 | Aventis Pharma Sa | Preparation d'adenovirus recombinants et de banques adenovirales |
| IL152450A0 (en) | 2000-05-12 | 2003-05-29 | Genzyme Corp | COMPOUNDS HAVING TNF-alpha SIGNAL MODULATING ACTIVITY |
| WO2003004620A2 (en) | 2001-07-05 | 2003-01-16 | Chiron, Corporation | Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof |
| US7569217B2 (en) * | 2001-09-24 | 2009-08-04 | University Of Saskatchewan | Porcine adenovirus E1 and E4 regions |
| US20030139374A1 (en) * | 2001-09-27 | 2003-07-24 | Board Of Regents, The University Of Texas System And Peregrine Pharmaceuticals, Inc. | Combined methods for tumor vasculature coagulation and treatment |
| EP1562571B1 (en) * | 2002-11-21 | 2011-08-17 | Genzyme Corporation | Combination of a diamide derivative and immunosuppressive agents for inhibiting transplant rejection |
| ATE493980T1 (de) * | 2002-11-21 | 2011-01-15 | Genzyme Corp | Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung |
| EP1725254A4 (en) * | 2004-02-04 | 2008-02-13 | Univ Columbia | ANTI-CD3 AND ANTIGEN-SPECIFIC IMMUNOTHERAPY FOR THE TREATMENT OF AUTOIMMUNITY |
| WO2008013918A2 (en) * | 2006-07-26 | 2008-01-31 | Myelin Repair Foundation, Inc. | Cell cycle regulation and differentiation |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5962694A (en) * | 1992-12-31 | 1994-08-15 | Exemplar Corporation | Producing cells for transplantation to reduce host rejection and resulting cells |
| WO1994016080A1 (en) * | 1993-01-08 | 1994-07-21 | Exemplar Corporation | An in vitro/in vivo method for identifying anti-neoplastic drugs |
| FR2705686B1 (fr) * | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
| US5872154A (en) * | 1995-02-24 | 1999-02-16 | The Trustees Of The University Of Pennsylvania | Method of reducing an immune response to a recombinant adenovirus |
-
1995
- 1995-02-14 FR FR9501662A patent/FR2730411B1/fr not_active Expired - Fee Related
-
1996
- 1996-02-12 DE DE69614668T patent/DE69614668T2/de not_active Expired - Lifetime
- 1996-02-12 WO PCT/FR1996/000218 patent/WO1996025177A1/fr not_active Application Discontinuation
- 1996-02-12 MX MX9706017A patent/MX9706017A/es unknown
- 1996-02-12 KR KR1019970705594A patent/KR100402540B1/ko not_active IP Right Cessation
- 1996-02-12 AU AU47238/96A patent/AU717218B2/en not_active Ceased
- 1996-02-12 CZ CZ972581A patent/CZ258197A3/cs unknown
- 1996-02-12 ES ES96903080T patent/ES2163612T3/es not_active Expired - Lifetime
- 1996-02-12 JP JP8524707A patent/JPH11500430A/ja not_active Ceased
- 1996-02-12 US US08/894,246 patent/US20030004091A1/en not_active Abandoned
- 1996-02-12 CA CA2211039A patent/CA2211039C/fr not_active Expired - Fee Related
- 1996-02-12 SK SK1108-97A patent/SK282235B6/sk not_active IP Right Cessation
- 1996-02-12 IL IL11711696A patent/IL117116A0/xx unknown
- 1996-02-12 DK DK96903080T patent/DK0809516T3/da active
- 1996-02-12 BR BR9607310A patent/BR9607310A/pt not_active Application Discontinuation
- 1996-02-12 HU HU9800635A patent/HU222991B1/hu not_active IP Right Cessation
- 1996-02-12 EP EP96903080A patent/EP0809516B1/fr not_active Expired - Lifetime
- 1996-02-12 PT PT96903080T patent/PT809516E/pt unknown
- 1996-02-12 AT AT96903080T patent/ATE204481T1/de active
- 1996-02-13 ZA ZA961161A patent/ZA961161B/xx unknown
-
1997
- 1997-08-13 NO NO19973724A patent/NO320072B1/no not_active IP Right Cessation
- 1997-08-13 FI FI973323A patent/FI119176B/fi not_active IP Right Cessation
-
2001
- 2001-08-23 GR GR20010400947T patent/GR3036438T3/el unknown
-
2004
- 2004-04-14 US US10/823,682 patent/US20040265276A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI973323A0 (fi) | Lääkeyhdistelmä, joka on käyttökelpoinen eksogeenien transfektioon ja ilmentämiseen in vivo | |
| BR9813202B1 (pt) | complexo de administração de genes; processo de transdução de células com material genético estranho, composição útil para administração de material genético e uso de um complexo de administração de genes. | |
| UA66417C2 (en) | Recombinant adenovirus affecting canines, pharmaceutical composition | |
| FI973467A (fi) | DNA-molekyylejä, valmistus ja käyttö geeniterapiassa | |
| HUP9800863A3 (en) | Drug delivery system for two or more active substances | |
| PT693924E (pt) | Processos para administracao (in vivo) de substancias biologicas e composicoes utilizadas nestes processos | |
| DK1037667T3 (da) | Farmaceutiske hydrogelformuleringer, lægemiddelindgivelsesanordninger samt fremgangsmåder | |
| AU2832297A (en) | Morphogen treatment for chronic renal failure | |
| GR3032744T3 (en) | Surface expression of enzyme in gene directed prodrug therapy | |
| FI95768C (fi) | Emättimensisäinen antosysteemi | |
| DE69823055D1 (de) | Abgabe von polyethylene glycol-molekül- konjugaten aus abbaubarem hydrogel | |
| DE69823481D1 (de) | Wegwerfbare, vorgefüllte medikamentenkartusche | |
| DE69700983D1 (de) | Ligandgerichtete enzyme-prodrug therapie | |
| AU2590697A (en) | Anesthetizing plastics, drug delivery plastics, and related medical products, s ystems and methods | |
| NO20020604D0 (no) | Fremgangsmåte for avlevering av terapeutiske midler ved bruk av en dekstrinlösning | |
| Agrawal | Antisense oligonucleotides as gene expression modulators | |
| AR004227A1 (es) | Uso de hialuronan en terapia genetica. | |
| MX9706569A (es) | Virus recombinantes que expresan la lecitina-colesterol aciltransferasa y sus usos en terapia genica. | |
| MX9803093A (es) | Suministro de polipeptidos biologicamente activos. | |
| IT239614Y1 (it) | Siringa salva vita. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 119176 Country of ref document: FI |
|
| MM | Patent lapsed |